Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

C4 Therapeutics (CCCC) Income from Continuing Operations (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Income from Continuing Operations data on record, last reported at 20365000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 41.1% year-over-year to 20365000.0; the TTM value through Dec 2025 reached 104873000.0, changed 0.42%, while the annual FY2025 figure was 104973000.0, 0.33% changed from the prior year.
  • Income from Continuing Operations reached 20365000.0 in Q4 2025 per CCCC's latest filing, up from 32166000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 15658000.0 in Q4 2021 and bottomed at 36584000.0 in Q4 2022.
  • Average Income from Continuing Operations over 5 years is 27680850.0, with a median of 26957500.0 recorded in 2022.
  • Peak YoY movement for Income from Continuing Operations: plummeted 133.64% in 2022, then soared 50.68% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 15658000.0 in 2021, then tumbled by 133.64% to 36584000.0 in 2022, then grew by 4.99% to 34757000.0 in 2023, then increased by 0.53% to 34573000.0 in 2024, then soared by 41.1% to 20365000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 20365000.0 in Q4 2025, 32166000.0 in Q3 2025, and 26020000.0 in Q2 2025.